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Cardiovascular diseases are the principal cause of death 
in the industrialized countries. Vascular wall calcification 
occurring in the late stages of cardiovascular diseases is 
an independent risk factor in patients with chronic kidney 
disease (CKD) (1,2). This process of arterial calcification 
in CKD may affect different arterial layers: the intima in 
association with atherosclerosis, and the media mostly in 
association with reduced kidney function (3). 
It is generally accepted that osteoblast-like cells, 
originating from dedifferentiated smooth muscle cells 
resident in the media, are responsible for the calcifications 
occurring in the arterial wall (4). The activation of this 
osteogenic program is triggered by injury and modulated 
by a number of inflammatory, metabolic, and genetic 
disorders (5). On a molecular point of view, the induction 
of bone morphogenetic proteins and osteochondrogenic 
transcription factors play a central role (6). Whereas 
this process is well established for calcifications of the 
tunica media, those occurring in the intimal layer are 
less characterized. The contribution of bone marrow-
derived circulating calcifying cells after the activation of 
an osteogenic program has been proposed (7). In a recent 
issue of Cell Stem Cell, Kramann and colleagues (8), using 
genetic fate mapping, clearly identified a new player in the 
calcification process: the mesenchymal stem cell (MSC) 
population located in the tunica adventitia. 
MSC, a population of mesenchymal cells with stem-like 
properties, have been detected in virtually all organs (9) 
as perivascular pericytes (10). In capillaries, these cells 
are in contact with the endothelium, and in large arteries 
localize in the external adventitial layer (11). Indeed, it 
must be noted that adventitia is rich in small vessels, i.e., 
vasa vasorum, that possibly represent the MSC niche. In 
a physiological context, MSC have been considered to 
mainly display a trophic function, stabilizing vessels and 
contributing to tissue and immune system homeostasis (12). 
MSC have been also actively involved in organ repair 
after injury in a variety of tissues (13). Consequently, 
administration of cultured MSC appears a promising tool 
for regenerative medicine. However, the lack of a specific 
MSC marker has hampered the possibility to trace their 
fate during damage and repair and to gain insights into 
the physio-pathological role of resident MSC. In fact, the 
characterization of MSC relies on the co-expression of 
a variety of mesenchymal markers shared by fibroblasts 
and other cell types. Recently, Gli1 has been shown to 
represent a specific selective marker for vascular MSC 
(14-16). By inducible genetic fate tracing experiments, 
Gli1+ MSC were reported to proliferate following injury 
and to differentiate into myofibroblasts in vivo (14). 
The effects resulting from the observed MSC activation 
appeared different and opposed in acute and chronic 
injury settings. During an acute vascular injury, due to 
wire injury of the femoral artery, Gli1+ cell differentiated 
into vascular smooth muscle cells and contributed to the 
healing effect. In particular, Gli1+ cells migrated into 
intima and media and replaced lost smooth muscle cells in 
the media. In parallel, other studies reported the activation 
and dedifferentiation of vascular smooth muscle cells, 
possibly deriving from Gli1+ cell themselves, after a vessel 
wall injury (17). These cells have been shown to undergo 
phenotypic changes, with production of less contractile 
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proteins, proliferation and migration into the neointima 
and media.
On the other hand, Gli1+ progenitor cells contributed to 
tissue fibrosis and calcifications in chronic injury settings 
(8,14). In fact, in a model of atherosclerosis in ApoE−/− 
mice with concomitant CKD, Gli1+ cells differentiated 
into osteoblast-like cells and significantly contributed to 
the arterial calcification process (8). In analogy, in chronic 
injury models of liver, lung, kidney or heart, the same 
authors showed that Gli1+ MSC promoted organ fibrosis. 
The relevance for human pathology, and in particular for 
the calcification occurring in CKD, has been confirmed by 
the detection of Gli1+ cells in human arteries from CKD 
patients.
These experiments together support a prominent 
negative effect of adventitial MSC in organ repair and 
identify Gli1+ cells as a possible therapeutic target. 
Importantly, the genetic ablation of Gli1+ cells before the 
induction of CKD significantly reduced the mineralization 
of the vascular wall (8). Similarly, Gli1+ cell ablation 
prevented the development of fibrosis in injured kidneys, 
liver and lungs (14,18,19). This opens a new strategy in the 
treatment of fibrosis and vascular calcifications that could be 
of benefit for patients with chronic diseases. On the light of 
the role of Gli as transcriptional effectors of the hedgehog 
pathway, pharmacological suppression of the hedgehog 
pathway itself resulted to reduce organ fibrosis (20).
Some questions rise from these studies. The first deals 
with the mechanisms of the epi-genetic changes of MSC 
involved in their transformation into detrimental cells. It 
is clear that the microenvironment occurring in chronic 
diseases may modulate MSC and favor their acquisition 
of a pro-calcifying phenotype (21,22). Indeed, the fibrotic 
and calcifying process occurring in CKD patients has been 
shown to result from a number of epigenetic changes in the 
tissue (23). Environment-induced changes in MSC should be 
considered for autologous MSC-based therapy. For example, 
it has been shown that tumor priming may converse MSC 
from an anti-tumor to a pro-tumorigenic phenotype (24). 
In addition, this detrimental environment may also affect 
heterologous MSC once administered to patients for 
regenerative purposes. Although many studies have shown 
the lack of toxic effects of MSC in clinical trials, their efficacy 
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